furosemide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   79 Trials   79 Trials   6783 News 


«12...6061626364656667686970...8687»
  • ||||||||||  rifampicin / Generic mfg., meropenem / Generic mfg., Daewon Pharmaceutical
    Journal:  Hyponatremia presenting with hourly fluctuating urine osmolality. (Pubmed Central) -  May 16, 2020   
    Repeated monitoring of urine chemistries aids in the diagnosis of the etiology underlying hyponatremia, including fever, in patients with transient ADH secretion. Glucocorticoid administration suppresses ADH secretion and improves hyponatremia even in the absence of adrenal insufficiency; the etiology of hyponatremia should be determined carefully in these patients.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD), cyclophosphamide intravenous / Generic mfg.
    [VIRTUAL] HIGH EFFICACY AND SAFETY OF CAR-T CELL THERAPY IN R/R B-ALL CHILDREN WITH HIGH LEUKEMIA BURDEN IN CENTRAL NERVOUS SYSTEM () -  May 16, 2020 - Abstract #EHA2020EHA_677;    
    Methods During November, 2018 and December, 2019, six patients who had high leukemia burden received sympathetic treatments, intrathecal injection and bridging chemotherapies contained high-dose dexamethasone and methotrexate were used to reduce leukemia burden in central nervous system...All patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3...Steroids (2 to 15 mg/kg/d methylprednisolone) were given by intravenous injection (IV) in patients with grade 3 CRES...One patient developed grade 4 CRES on day 4 after CAR T-cell infusion as manifested by apnea and was immediately managed with mannitol and furosemide to reduce intracranial pressure, and dexamethasone to alleviate inflammation, and completely resolved on day 8...However, the occurrence of CRES properly high in patients with high leukemia burden CNSL. The intravenous injection of Mannitol and steroids and intrathecal injection of Dex can effective control CRES and help these kind of patients.
  • ||||||||||  furosemide / Generic mfg.
    Journal, Adverse events:  Avoiding Furosemide Ototoxicity Associated With Single-Ventricle Repair in Young Infants. (Pubmed Central) -  May 13, 2020   
    A practice change to ensure slow IV administration of furosemide eliminated permanent hearing loss. Centers caring for critically ill infants, particularly those with single-ventricle anatomy or hypoxia, should review their drug administration guidelines and adhere to best practice for administration of IV furosemide.
  • ||||||||||  pecavaptan (BAY1753011) / Bayer
    Trial completion date, Trial primary completion date:  AVANTI: A Trial to Study BAY1753011 in Patients With Congestive Heart Failure (clinicaltrials.gov) -  May 13, 2020   
    P2,  N=414, Recruiting, 
    Centers caring for critically ill infants, particularly those with single-ventricle anatomy or hypoxia, should review their drug administration guidelines and adhere to best practice for administration of IV furosemide. Trial completion date: Jul 2020 --> May 2021 | Trial primary completion date: Jun 2020 --> Apr 2021
  • ||||||||||  furosemide / Generic mfg.
    Journal:  Sox6 as a new modulator of renin expression in the kidney. (Pubmed Central) -  May 13, 2020   
    In vivo, Sox6 expression is upregulated after a low-Na diet and furosemide...Furthermore, Sox6 ablation in renin expressing cells halts the recruitment of smooth muscle cells along the afferent arteriole to express renin under the same conditions. These results support a previously undefined role for Sox6 in renin expression.
  • ||||||||||  furosemide / Generic mfg.
    Review, Journal:  Subcutaneous furosemide for the treatment of heart failure: a state-of-the art review. (Pubmed Central) -  May 11, 2020   
    Subcutaneous furosemide use will potentially overcome the need to place intravenous lines, reduce associated expenses, and enable management of ADHF at home. This review presents data on the pharmacodynamics and pharmacokinetics of subcutaneous furosemide, scientific evidence on the use of this therapy in the palliative and hospice population, and its experimental use as an outpatient therapy and/or as a bridge from inpatient to home.
  • ||||||||||  furosemide / Generic mfg.
    Trial completion:  ForBP: Furosemide for Accelerated Recovery of Blood Pressure Postpartum (clinicaltrials.gov) -  May 11, 2020   
    P2,  N=384, Completed, 
    This review presents data on the pharmacodynamics and pharmacokinetics of subcutaneous furosemide, scientific evidence on the use of this therapy in the palliative and hospice population, and its experimental use as an outpatient therapy and/or as a bridge from inpatient to home. Recruiting --> Completed
  • ||||||||||  furosemide / Generic mfg.
    Journal:  Subcutaneous fat necrosis of the newborn. (Pubmed Central) -  May 11, 2020   
    Initial calcium was normal, however hypercalcaemia requiring hyperhydration and furosemide developed at 4 weeks...Persistent calcinosis was present in 6%. Babies treated with therapeutic hypothermia should be closely monitored for SFNN, and development of hypercalcaemia.
  • ||||||||||  Trial completion:  NID-2: Nephropathy In Type 2 Diabetes and Cardio-renal Events (clinicaltrials.gov) -  May 11, 2020   
    P4,  N=850, Completed, 
    Babies treated with therapeutic hypothermia should be closely monitored for SFNN, and development of hypercalcaemia. Active, not recruiting --> Completed
  • ||||||||||  furosemide / Generic mfg.
    Journal:  LC-MSMS based screening of emerging pollutant degradation by different peroxidases. (Pubmed Central) -  May 9, 2020   
    LC-MSMS approaches, like the one described here, can be used to rapidly evaluate the potential of different peroxidases (and redox requirements) to be used as bioremediation agents. Our preliminary result shows peroxidases hold tremendous potential for being used in a final wastewater treatment step.
  • ||||||||||  Retrospective data, Review, Journal:  Efficacy of pharmacotherapy for OSA in adults: A systematic review and network meta-analysis. (Pubmed Central) -  May 7, 2020   
    In the network meta-analysis (I = 50%) nine drugs (tramazoline, liraglutide, spironolactone/furosemide, acetazolamide, dronabinol, zonisamide, phentermine, spironolactone, and ondansetron/fluoxetine) significantly lowered the AHI compared to placebo...The effect sizes were small, the majority of trials were not adequately powered. There is currently insufficient evidence to recommend any pharmacotherapy for OSA and no phase-III trials are available.
  • ||||||||||  Actimab-A (lintuzumab-Ac225) / Actinium
    Trial completion date:  Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients (clinicaltrials.gov) -  May 7, 2020   
    P1/2,  N=72, Active, not recruiting, 
    Infants with severe BPD are exposed to alarming number of medications of unclear efficacy and safety, with marked variation between center. Trial completion date: Jun 2020 --> Dec 2020
  • ||||||||||  furosemide / Generic mfg.
    Journal:  Visualization of the intrarenal distribution of capillary blood flow. (Pubmed Central) -  May 1, 2020   
    Infusion of angiotensin II, hypotension, volume expansion, and mannitol- or furosemide-induced diuresis redistributed flow between renal cortical and medullary capillaries. The advantage of the current technique is that it provides anatomical information regarding the number, diameter, and branching patterns of capillaries in the postglomerular circulation critical in determining the intrarenal distribution of cortical and medullary blood flow.
  • ||||||||||  furosemide / Generic mfg.
    Retrospective data, Journal:  Thrombolysis with tissue plasminogen activator (TPA) in feline acute aortic thromboembolism: a retrospective study of 16 cases. (Pubmed Central) -  May 1, 2020   
    The most common regimen received for TPA was 1 mg/kg over 1 h. Other treatments were similar to those of the SOC group and included analgesia, thromboprophylaxis and furosemide...There were no differences in short-term survival rate (56.2% vs 39.5%; P = 0.369), clinical improvement (56.2% vs 31%; P = 0.122), rates of reperfusion injury (50% vs 50%; P = 1.00) or AKI (30% vs 27%; P = 1.00) between the TPA-treated and SOC groups, respectively. Conclusions and relevance Survival and complication rates of TPA-treated cats and SOC-treated cats for acute FATE were similar.
  • ||||||||||  digoxin / Generic mfg., furosemide / Generic mfg., labetalol / Generic mfg.
    Journal:  Review of Cardiovascular Drugs in Pregnancy. (Pubmed Central) -  Apr 29, 2020   
    Heart failure medications, including beta-blockers, furosemide, and digoxin, are relatively safe and can be used effectively...A summary of the safety of drugs during pregnancy and lactation from an online resource, LactMed by the National Library of Medicine's TOXNET database, is included. High-risk pregnant patients with cardiovascular disease require a multispecialty team of doctors, including health care providers from obstetrics and gynecology, maternal fetal medicine, internal medicine, cardiovascular disease specialists, and specialized pharmacology expertise.
  • ||||||||||  furosemide / Generic mfg.
    Trial completion date, Trial primary completion date:  ERES-HFpEF: Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) -  Apr 28, 2020   
    P1,  N=15, Recruiting, 
    High-risk pregnant patients with cardiovascular disease require a multispecialty team of doctors, including health care providers from obstetrics and gynecology, maternal fetal medicine, internal medicine, cardiovascular disease specialists, and specialized pharmacology expertise. Trial completion date: Apr 2020 --> Aug 2020 | Trial primary completion date: Apr 2020 --> Aug 2020
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, Rovi Pharmaceuticals Laboratories
    Sacubitril-Valsartan Improves Blood Pressure and Heart Failure in Left Ventricular Assist Device (LVAD) Patients () -  Apr 26, 2020 - Abstract #ISHLT2020ISHLT_1095;    
    ARNI also facilitated a significant reduction in loop diuretic requirement (furosemide equivalent of 132±136 to 80±65.6 mg/day, P=0.004)...Conclusion ARNI can improve blood pressure, decrease diuretic requirement, and improve functional capacity in LVAD patients. LVAD speed and medication adjustments may be necessary following ARNI initiation, and in some instances, side effects can limit the ability to sustain ARNI therapy in the setting of LVAD.
  • ||||||||||  furosemide / Generic mfg.
    Cardiac Autonomic Nerves Stimulation Improves Hemodynamics and Clinical Status in Advanced Heart Failure Patients () -  Apr 26, 2020 - Abstract #ISHLT2020ISHLT_494;    
    Patients received at least 80 mg/day of furosemide, had minimal change to existing heart failure medical management, received no new IV vasoactive therapies, and a majority of the patients (17/22) received no furosemide dose uptitration during CANS Therapy. Conclusion Alongside concomitant medical therapy, CANS holds promise as a tool to improve in-hospital hemodynamics and relieve congestion.
  • ||||||||||  furosemide / Generic mfg.
    Angiotensin Receptor Neprilysin Inhibition in Patients with Left Ventricular Assist Devices () -  Apr 26, 2020 - Abstract #ISHLT2020ISHLT_7;    
    Prior to ARNI initiation, 47% were on ACE inhibitor, 13% on ARB, 40% on neither and 60% were treated with diuretics, with an average oral furosemide equivalent dose of 34 mg/day...There was a significant decrease in NT-proBNP levels, an effect previously reported in HF pts without LVADs in the PARADIGM-HF and PIONEER-HF trials. Randomized studies to determine the role of ARNI on the clinical course of LVAD patients are warranted.
  • ||||||||||  ceftriaxone / Generic mfg.
    Clinical, Journal:  Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia: A Rare Case Report from Nephrology. (Pubmed Central) -  Apr 26, 2020   
    The treatment with steroids lasted for 1 day only, and in the following day, the patient was switched to prednisone (20 mg/day orally) for only 1 additional day...CONCLUSIONS Herein, we present a case of a patient with stable chronic lymphocytic leukemia, who developed spontaneous tumor lysis syndrome after short low dose of steroid therapy. This case highlights the importance of including spontaneous tumor lysis syndrome in the differential diagnosis of any acute renal failure in the constellation of any malignancy.